Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353938 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4961187 | 0.88 | CTSK (0.56) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4583120 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL56698 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL56596 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL19517266 | 0.88 | CTSK (0.56) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL10324741 | 0.87 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL27594478 | 0.87 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL21219239 | 0.87 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL6007487 | 0.87 | CTSK (0.52) | CTSKCTSSMAPTATMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | disclosed |